Speaker: Christopher J. Lettieri, MD, Respiratory Care Specialist, Pulmonary and Critical Care Service, Department of Medicine, Walter Reed Army Medical Center, Washington, DC. Treatment with gamma-interferon 1b (IFN) (Actimmune®, InterMune) resulted in enhanced functional capacity and improved exercise tolerance in patients with idiopathic pulmonary fibrosis (IPF) when compared with control patients with IPF who were [...]

Speaker: Horst Olschewski, MD, Professor and Chair, Division of Pulmonary Medicine, Medical University Clinic, Medical University, Graz, Austria. In a subset analysis of patients with New York Heart Association (NYHA) class IV pulmonary hypertension (PH), treatment with iloprost (Ventavis®, CoTherix, Inc.), a prostacyclin that offers a noninvasive inhaled dosing approach, resulted in a significant improvement [...]

Speaker: Anthony D. P’Urzo, MD, MSc, Family Physician and Director, Primary Care Asthma Clinic, and Lecturer, Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada. The combination of AstraZeneca’s budesonide (Pulmicort®) and formoterol (Oxis® [BUD/FORM]) (Symbicort®, Single Inhaler Therapy™, AstraZeneca, Canada), administered for both maintenance and relief in patients with asthma, reduced [...]

Nebulized Levalbuterol in Elderly Patients with Asthma Speaker: Ronald J. Ozminkowski, PhD, Senior Economist, Outcomes Research and Economics, Research and Policy Group, The Medstat Group, Thomson Corporation, Ann Arbor, Michigan. In an exploratory analysis of data collected on the management of elderly Medicaid patients with clinical asthma treatment with nebulized levalbuterol (Xopenex®, Sepracor, Inc.) resulted [...]